For the quarter ending 2025-09-30, PTGX had -$54,833K decrease in cash & cash equivalents over the period. -$2,025K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue | 4,712 | - |
| Discovery department expenses (excluding employee wages and benefits, stock-based compensation and expense allocations) | 21,410 | - |
| Development department expense (excluding employee wages and benefits, stock-based compensation and expense allocations) | 75,711 | - |
| General and administrative expenses (excluding employee wages and benefits, stock-based compensation and expense allocations) | 28,927 | - |
| Employee wages and benefits - discovery | 11,464 | - |
| Employee wages and benefits - development | 25,548 | - |
| Employee wages and benefits - general and administrative | 18,522 | - |
| Stock-based compensation expense | 59,987 | - |
| Other segment items | -269 | - |
| Interest income | 7,049 | - |
| Income tax benefit (expense) | 344 | - |
| Net (loss) income | -39,339 | -46,426 |
| Stock-based compensation | 10,559 | 24,714 |
| Non-cash lease expense | 106 | 1,137 |
| Depreciation | 361 | 543 |
| Accretion of discount on marketable securities | 1,684 | 4,203 |
| Net realized loss on sale of marketable securities | 1 | -5 |
| Receivable from collaboration partner | 583 | -165,000 |
| Prepaid expenses and other assets | -50 | 2,045 |
| Accounts payable | 2,418 | 1,612 |
| Contract asset | - | 22,287 |
| Accrued expenses and other payables | 7,545 | -8,378 |
| Income taxes payable | 0 | -2,689 |
| Deferred revenue | -3,075 | -10,504 |
| Operating lease liability | -581 | 104 |
| Net cash provided by operating activities | -1,937 | 96,583 |
| Purchase of marketable securities | 161,117 | 281,194 |
| Proceeds from maturities of marketable securities | 102,650 | 235,957 |
| Proceeds from sale of marketable securities | 0 | 7,003 |
| Purchases of property and equipment | 88 | 1,358 |
| Net cash used in investing activities | -58,555 | -39,592 |
| Proceeds from issuance of common stock upon exercise of stock options and purchases under employee stock purchase plan | 5,659 | 14,847 |
| Tax withholding payments related to net settlement of restricted stock units | 0 | 479 |
| Net cash provided by financing activities | 5,659 | 14,368 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -54,833 | 71,359 |
| Cash and cash equivalents at beginning of period | 97,474 | - |
| Cash and cash equivalents at end of period | 114,000 | - |
Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc (PTGX)